• 1
    Keith NM, Wagener HP, Barker NW. Some different types of essential hypertension: their course and prognosis. Am J Med Sci. 1974;268:336345.
  • 2
    Kincaid-Smith P, McMichael J, Murphy EA. The clinical course and pathology of hypertension with papilloedema (malignant hypertension). Q J Med. 1958;27:117153.
  • 3
    Stevens AA. The Practice of Medicine. Philadelphia, PA: WB Saunders Co; 1926.
  • 4
    Moser M. The Treatment of Hypertension. A Story of Myths, Misconceptions, Controversies, and Heroics. 2nd ed. Darien, CT: Le Jacq Communications Inc; 2002.
  • 5
    Bishop LF. Heart Disease and Blood-Pressure. A Practical Consideration of Theory and Treatment. 2nd ed. New York, NY: EB Treat & Company; 1907.
  • 6
    Butler GR. The Diagnostics of Internal Medicine. New York, NY: D Appleton & Co; 1913.
  • 7
    Swift PA, MacGregor GA. Genetic variation in the epithelial sodium channel: a risk factor for hypertension in people of African origin. Adv Ren Replace Ther. 2004;11:7686.
  • 8
    Grubbs AL, Ergul A. A review of endothelin and hypertension in African American individuals. Ethn Dis. 2001;11:741748.
  • 9
    Kalinowski L, Dobrucki IT, Malinski T. Race-specific differences in endothelial function: predisposition of African Americans to vascular diseases. Circulation. 2004;109:25112517.
  • 10
    Lopes AA, Port FK. The low birth weight hypothesis as a plausible explanation for the black/white differences in hypertension, non-insulin-dependent diabetes, and end-stage renal disease. Am J Kidney Dis. 1995;25:350356.
  • 11
    Jean-Louis G, Zizi F, Casimir G, et al. Sleep-disordered breathing and hypertension among African Americans. J Hum Hypertens. 2005;19:485490.
  • 12
    Flegal KM, Carroll MD, Ogden CL, et al. Prevalence and trends in obesity among US adults, 1999–2000. JAMA. 2002;288:17231727.
  • 13
    American Heart Association. Heart Disease and Stroke Statistics—2004 Update. Dallas, TX: American Heart Association; 2004.
  • 14
    The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289:25602572.
  • 15
    Appel LJ, Moore TJ, Obarzanek E, et al. A clinical trial of the effects of dietary patterns on blood pressure. DASH Collaborative Research Group. N Engl J Med. 1997;336:11171124.
  • 16
    Sacks FM, Svetkey LP, Vollmer WM, et al. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group. N Engl J Med. 2001;344:310.
  • 17
    Wright JT Jr, Agodoa L, Contreras G, et al. Successful blood pressure control in the African American Study of Kidney Disease and Hypertension. Arch Intern Med. 2002;162:16361643.
  • 18
    Cushman WC, Ford CE, Cutler JA, et al. Success and predictors of blood pressure control in diverse North American settings: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). J Clin Hypertens (Greenwich). 2002;4:393405.
  • 19
    Effects of treatment on morbidity in hypertension. II. Results in patients with diastolic blood pressure averaging 90 through 114 mm Hg. JAMA. 1970;213:11431152.
  • 20
    Hypertension Detection and Follow-up Program Cooperative Group. Five-year findings of the hypertension detection and follow-up program. II. Mortality by race-sex and age. JAMA. 1979;242:25722577.
  • 21
    Johnson EF, Wright JT Jr. Management of hypertension in black populations. In: WeberMA, Oparil S, eds. Hypertension. Philadelphia, PA: Elsevier; 2005:587595.
  • 22
    Wright JT Jr, Dunn JK, Cutler JA, et al. Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinopril. JAMA. 2005;293:15951608.
  • 23
    Julius S, Alderman MH, Beevers G, et al. Cardiovascular risk reduction in hypertensive black patients with left ventricular hypertrophy: the LIFE study. J Am Coll Cardiol. 2004;43:10471055.
  • 24
    Leenen FH, Nwachuku CE, Black HR, et al. Clinical events in high-risk hypertensive patients randomly assigned to calcium channel blocker versus angiotensin-converting enzyme inhibitor in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. Hypertension. 2006;48:374384.
  • 25
    Du Bois WEB. Writings. New York, NY: Library of America; 1986:392.
  • 26
    Armstrong SC. To George Washington Campbell [letter]. In: HarlanLR, Daniel P, eds. The Booker T. Washington Papers.Vol. 2. Urbana, IL: University of Illinois Press; 1972:127.
  • 27
    Taylor AL, Wright JT Jr. Should ethnicity serve as the basis for clinical trial design? Importance of race/ethnicity in clinical trials. Lessons from the African American Heart Failure Trial (A-HeFT), the African American Study of Kidney Disease and Hypertension (AASK), and the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Circulation. 2005;112:36543666.